国药控股(01099)：国药股份(600511.SH)2025年归属于母公司净利润 19.97 亿元 同比下降 0.18%

Core Viewpoint - China National Pharmaceutical Group (国药控股) reported its subsidiary China National Pharmaceutical Co. (国药股份) achieved a revenue of 52.468 billion yuan in 2025, reflecting a year-on-year increase of 3.70% [1] Financial Performance - Total profit amounted to 2.600 billion yuan, showing a year-on-year decline of 2.01% [1] - Net profit reached 2.089 billion yuan, down by 1.90% compared to the previous year [1] - Profit attributable to the parent company was 1.997 billion yuan, a slight decrease of 0.18% year-on-year [1] - The net profit excluding non-recurring items attributable to the parent company was 1.971 billion yuan, down 1.28% year-on-year [1] - The net cash flow from operating activities was 2.006 billion yuan [1] Balance Sheet Highlights - As of December 31, 2025, total assets were 36.685 billion yuan [1] - Equity attributable to shareholders of the listed company stood at 18.545 billion yuan [1] - The weighted return on equity was 11.26% [1]